Drug Database
RA

rabies immunoglobulin (human) (HyperRAB S/D)

✓ Approved

Grifols, S.A. · Polyclonal Antibodies · Polyclonal Antibodies

What is rabies immunoglobulin (human)?

rabies immunoglobulin (human) is a polyclonal antibodies developed by Grifols, S.A.. It is approved for therapeutic indications via injectable (others) or intramuscular (im) injection.

Drug Profile

Brand NamesHyperRAB S/D
CompanyGrifols, S.A.
Drug ClassPolyclonal Antibodies, Antibody
RouteInjectable (Others), Intramuscular (IM) Injection
StatusApproved
Sources: ClinicalTrials.gov, Grifols, S.A.

Therapeutic Indications

rabies immunoglobulin (human) is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsRabies✓ Approved

Related Research Articles

PubMedRevue medicale suisse2026-10-22

[Nightmare or wonder : a bat on the ceiling].

Ménard Agathe A, Erard Véronique V

Rabies is an invariably fatal zoonosis in humans caused by a neurotropic virus of Lyssavirus genus. Three genotypes are endemic in Europe. Genotype 1 or RABV (Rabies lyssavirus) is the agent of classical rabies, for which dogs and certain wild carnivores serve as reservoirs; genotypes 5 and 6, respectively EBLV-1 and EBLV-2 (European bat lyssavirus type 1 and 2), have bats as reservoirs. In Switzerland, classical rabies (RABV) has been eradicated since 1999, a status shared by the majority of European Union countries. Cases of human rabies encephalitis transmitted by bats in Europe are associated with EBLV-1 and EBLV-2 but are exceptional. This article aims to present the epidemiology, pathogenesis and prevention of rabies in Switzerland.

PMID 42902968
Read full article →
PubMedRevue medicale suisse2026-10-22

[Bucket-list destinations from an infectious disease perspective].

Grounauer Louise S LS, Prongué Estelle E, Zumbrunn Samuel K SK, Calamai Pietro P et al.

Tropical countries are among the most popular destinations for Swiss travelers and pose a health challenge in terms of infectious disease risk. Arboviral diseases are one of the major infectious risks, along with rabies, hepatitis A, and malaria. Several resurgences of vaccine-preventable diseases, such as polio and yellow fever, have also been identified. In light of these data, it would appear that the safest travel destinations from an infectious disease perspective are Cuba in Latin America, Hong Kong in Asia, and the Seychelles in Africa. However, these data are subject to change and may evolve rapidly.

PMID 42902966
Read full article →
PubMedJournal of clinical laboratory analysis2026-10-22

The Impact of Immunoglobulins on Cardiovascular Diseases and Lipid Profiles in Elderly and Middle-Aged Chinese Individuals: A 15-Year Retrospective Study.

Li Ya Y, Jiao Li L, Gao Yuan Y, Ni Xue-Feng XF

Humoral immunity defends via immunoglobulins. This study aimed to evaluate the association between immunoglobulins and CVDs and lipid profiles in a cohort of individuals aged 45 years and older. Data from 982 subjects were analyzed. The cohort had a median age of 61 years (IQR 56-72), was predominantly male (84.8%), and had a high prevalence of CVDs at baseline, including hypertension (30.3%), dyslipidemia (20.7%), arrhythmia (22.3%), coronary heart disease (12.1%), and atrial fibrillation (4.5%). Logistic regression analysis was used to examine the association between baseline and time-varying serum levels of IgG, IgA, and IgM and the presence of five CVDs: coronary heart disease, atrial fibrillation, arrhythmia, hypertension, and dyslipidemia. We additionally explored the relationship between these immunoglobulin levels and lipid profiles. No significant differences in immunoglobulin levels were found between CVD and non-CVD groups at baseline, and baseline immunoglobulin levels were not associated with any CVD. However, longitudinal changes in IgG and IgA levels were positively associated with changes in free fatty acids (FFAs). Intriguingly, longitudinal increases in IgM levels were positively associated with total cholesterol, LDL-C, non-HDL-C, and HDL-C. This study provides longitudinal evidence that increases in IgG and IgA levels are associated with elevated FFA levels, while increases in IgM are associated with an adverse lipid profile characterized by higher total cholesterol, LDL-C, and non-HDL-C, and lower HDL-C. These findings suggest a link between humoral immunity and lipid metabolism that warrants further investigation, with potential implications for cardiovascular risk assessment.

PMID 42902915
Read full article →
PubMedAmyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis2026-10-22

Quality standards for the diagnosis and management of ATTR and AL amyloidosis: a nominal group technique study.

Obici Laura L, Damy Thibaud T, Galan Lucia L, Moody William W et al.

Transthyretin (ATTR) and immunoglobulin light-chain (AL) amyloidosis are progressive conditions that can have debilitating effects on people. Delayed diagnosis and variable access to high-quality care continue to affect quality of life and prognosis. Clear and ambitious quality standards could drive consistent care and improve outcomes. A modified nominal group technique was used to develop consensus-based quality standards for the diagnosis and management of ATTR and AL amyloidosis. Eighteen experts participated, including patient representatives and clinicians from high-income, publicly funded health systems in Europe and Canada. Each quality standard was paired with at least one measurable indicator to support implementation and monitoring. A total of 29 provisional statements were generated, with consensus achieved on eight quality standards. These span the full care pathway and emphasise the need for timely, person-centred and interdisciplinary care. Twenty accompanying indicators were developed. This is the first comprehensive set of consensus-based quality standards for ATTR and AL amyloidosis care. They provide a practical and aspirational framework to guide quality improvement across health systems. Adoption of these standards could improve early diagnosis, equitable access to treatment, and quality of life. Future research may explore their feasibility and adaptation for other health system settings.

PMID 42902796
Read full article →
PubMedFrontiers in immunology2026-10-22

Case Report: Acute liver failure in systemic lupus erythematosus with autoimmune hepatitis-primary biliary cholangitis overlap: a belimumab-containing regimen and longitudinal follow-up.

Zhang Lina L, Zhang Tong T, Zhang Jing J, Wang Xiuhong X et al.

Severe autoimmune liver injury as the first manifestation of systemic lupus erythematosus (SLE) is rare, and concomitant autoimmune hepatitis-primary biliary cholangitis (AIH-PBC) overlap is uncommon. B-cell-activating factor (BAFF) provides a biological rationale for adjunctive therapy, although clinical evidence remains limited. A 72-year-old woman presented with 4 weeks of fatigue and anorexia and developed coagulopathy (international normalized ratio [INR] 1.8), ascites, and hepatic encephalopathy. Autoimmune testing showed antinuclear antibody 1:1280, high-titer anti-double-stranded DNA antibodies with hypocomplementemia, immunoglobulin G (IgG) 30.0 g/L, and antimitochondrial antibody positivity. Hepatitis B surface antigen, hepatitis C antibody, hepatitis E antibody, and Epstein-Barr virus and cytomegalovirus DNA tests were negative. Liver biopsy 42 days after corticosteroid initiation demonstrated interface hepatitis, destructive small-bile-duct injury, plasma cell-rich inflammation, and Batts-Ludwig stage 2 fibrosis without cirrhosis, supporting a clinicopathologic diagnosis of AIH-PBC overlap. Previously unrecognized chronic autoimmune liver disease could not be excluded. Prednisolone was started at 50 mg/day, followed 10 days later by intravenous belimumab, with concomitant ursodeoxycholic acid. Tacrolimus was added during maintenance. By 10 October 2025, liver biochemistry had improved, IgG was 9.42 g/L, and prednisolone had been reduced to 2.5 mg/day. Liver stiffness decreased from 21.5 to 9.7 kPa. Sustained biochemical improvement occurred during a belimumab-containing multidrug regimen. This observation does not establish the independent efficacy of belimumab or histological regression of fibrosis.

PMID 42903101
Read full article →
PubMedZhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics2026-10-22

[Post-discharge fortified human milk feeding in preterm infants with moderate-to-high nutritional risk: a retrospective cohort study].

Wang Yun-He YH, Yao Yi Y, Chi Yun-Qian YQ, Zhang Zi-Han ZH et al.

To investigate the effects of post-discharge fortified human milk feeding on growth, common complications, and neuropsychological development in preterm infants with moderate-to-high nutritional risk. Clinical data were retrospectively collected from 320 preterm infants with moderate-to-high nutritional risk who were discharged from the Department of Neonatology, Provincial Hospital Affiliated to Shandong First Medical University between January 2021 and December 2023 and completed a 6-month follow-up. Infants were classified into four groups by nutritional risk level and feeding method: moderate-risk fortified human milk, moderate-risk formula, high-risk fortified human milk, and high-risk formula. Comparisons were conducted between fortified human milk and formula within the same risk level, and between moderate- and high-risk groups within the same feeding method. Within the same feeding method, gestational age at birth and birth weight differed significantly between moderate- and high-risk infants (P<0.001). Within the same nutritional risk level, no significant differences were found between fortified human milk and formula groups in gestational age at birth and birth weight (P>0.05). In the fortified human milk groups, corrected gestational age at discharge differed significantly between moderate- and high-risk infants (P<0.05). No significant differences were noted among the four groups in discharge weight, length, or head circumference (P>0.05). Analysis of covariance, adjusting for discharge weight, length, head circumference, and corrected gestational age at discharge, showed no significant differences among the four groups during the 6-month follow-up in growth velocities of weight, length, or head circumference, nor in hemoglobin, 25-hydroxyvitamin D, or alkaline phosphatase measured at 1, 3, and 5 months (P>0.05). Multivariable logistic regression indicated that fortified human milk feeding did not increase the risk of infection (OR=0.66, 95%CI: 0.40-1.08, P=0.097) or feeding intolerance (OR=0.70, 95%CI: 0.45-1.08, P=0.107). At 6 months' corrected age, mental, motor, and behavioral scores did not differ significantly among groups (P>0.05). In preterm infants at moderate-to-high nutritional risk, post-discharge fortified human milk feeding does not increase the risk of infection or feeding intolerance, does not differ significantly from formula feeding in short-term catch-up growth or neuropsychological development, and appears clinically feasible and safe.

PMID 42902717
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about rabies immunoglobulin (human)